Abstract
ACC & TNBC are tumors associated with Notch signaling pathway dysregulation. Ayala is targeting Notch activated tumors with investigational small molecule pan-Notch γ-secretase inhibitors AL101 & AL102. AL101 is currently being investigated in 2 phase II open-label, single-arm, multicenter studies in ACC (ACCURACY; NCT03691207) and TNBC (TENACITY; NCT04461600) in patients harboring known Notch1-4 activating alterations. Notch interacts via crosstalk with other signaling pathways, and here we describe testing for their identity to provide guidance for future combination studies with AL101.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
